On 14 April 2026, the China State Council Office Notice Guobanfa [2026] No. 9 ( 国办发[2026] 9号 ), Opinions on Improving the Drug Price Formation Mechanism. It is the first national framework document on drug pricing issued under the authority of the State Council Office since 2015, when China abolished government-set drug prices. At a policy briefing the following day, NHSA Director of Drug Pricing and Procurement, Wang Xiaoning, stated that volume-based procurement “does not cover innovative drugs.” That statement, combined with the document’s text, has been widely read as a turning point for innovation pricing. The reading is directionally correct but operationally premature, and for companies in the device and consumable sector, the distance between the signal and an executable rule is significant.

What the Document Actually Says

Three mechanisms are established or formalised by the document:

A first-launch pricing mechanism for new drugs. Newly listed drugs will operate under an enterprise self-assessment system, with companies setting prices based on clinical value, market conditions, competitive landscape, and social affordability. For high-level innovative drugs with high clinical value, the document supports pricing commensurate with high investment and high risk at the time of launch, with relative price stability maintained “for a defined period.” The duration of that period is not specified in the document and was not defined at the press briefing. It is an intentionally open parameter, subject to forthcoming implementation guidelines.

A commercial insurance pathway for innovative drugs. The document formally incorporates commercial health insurance as a payment channel for innovative drugs, and references the accelerated implementation of the Commercial Health Insurance Innovative Drug List. The first edition of that list, covering 19 drugs including CAR-T therapies and an Alzheimer’s treatment, took effect on 1 January 2026. Products on the list carry three administrative exemptions: they are excluded from hospital self-pay ratio assessments, excluded from VBP-substitute monitoring, and excluded from DRG/DIP episode payment calculations.

A normalised VBP framework targeting mature, multi-supplier drugs. The document defines the scope of volume-based procurement as drugs that are “multi-sourced and long-established.” This is the basis for Wang Xiaoning’s statement that VBP does not cover innovative drugs. It is a clarification of scope, not a new exemption. VBP was designed for commoditised products and was never intended for first-launch innovations. What is new is the explicit national codification of this boundary.

From the original text: “For high-level innovative drugs with high innovation and high clinical value, [the State Council] supports pricing commensurate with high investment and high risk at the time of market launch, and maintaining relatively stable prices for a defined period.”

(Original: “对创新程度高、临床价值大的高水平创新药，支持在上市初期制定与高投入、高风险相符的价格，在一定时期内保持价格相对稳定。”)

The Two Execution Gaps That Matter

Gap one: the innovation recognition standard does not yet exist. The document supports pricing protection for drugs with “high level of innovation” and “high clinical value”, but the criteria for making that determination are described as “under development.” No operational definition has been published. No self-assessment template is available. Until these criteria are established and the first-launch price mechanism is implemented, companies cannot use this framework to defend a price. The signal is real; the instrument is not yet ready.

Gap two: the device sector requires its own document. The policy-execution gap is most significant for companies in the medical device and consumable sector. Document [2026] No. 9 has explicit legal force over drugs. Its application to medical devices requires independent action by NMPA and NHSA, separate regulatory instruments that have not been initiated as of the document’s publication. Companies in ophthalmics, orthopaedics, cardiovascular devices, or any other high-value consumable category cannot cite No. 9 as the basis for a pricing or procurement argument. The logic may transmit; the rule has not.

Commercial Insurance: A Third Channel, With Limits

The commercial insurance mechanism deserves attention separately from the VBP question, because it is already operational rather than pending.

The first Commercial Health Insurance Innovative Drug List is live. As of 1 January 2026, the list covers 19 drugs. Several cities have moved quickly: Shenzhen’s Huimin Bao product has incorporated all 19 drugs into its 2025 coverage; Shantou’s version raises the reimbursement ratio by ten percentage points for hospitalisation involving listed products. In 2024, city-level supplemental insurance and million-yuan medical insurance products combined paid approximately RMB 4.5 billion in innovative drug costs, a growing but still narrow figure relative to basic insurance’s RMB 460 billion expenditure on negotiated drugs.

Device coverage exists in parallel. Several Chinese commercial health insurance products already cover high-value medical consumables outside the basic insurance scope. Jiangsu’s 2026 Medical Huibao covers medical-insurance-excluded high-value consumables. Guangzhou’s Suixinbao covers innovative drugs and devices approved under the Greater Bay Area drug and device access scheme. Shanghai’s Lingang Blue Bay Plan covers new consumables not yet in the standard insurance catalogue. These products operate outside the national Innovative Drug List framework but serve the same structural function: bridging the gap between basic insurance coverage and clinical reality.

The structural limit. The Commercial Innovative Drug List is a reference document, not a mandate. Insurance companies incorporate listed products voluntarily. Coverage penetration varies significantly across cities and products. For device companies, no equivalent national list currently exists; the device-side commercial insurance coverage is city-specific and product-specific, without a central framework to accelerate adoption.

What This Means for Multinational Healthcare Companies

Companies such as Alcon, Zeiss, Johnson & Johnson, Novartis, and Roche operate across drugs, devices, and consumables simultaneously. Document [2026] No. 9 affects these portfolios asymmetrically.

For the drug portfolio: the strategic window is opening. A multinational company launching an innovative drug in China for the first time now has a national framework that explicitly supports early-launch pricing commensurate with R&D investment. This changes the global launch sequencing calculation, China has historically been excluded from or deprioritised in global launch waves because of its price-suppression environment. Document [2026] No. 9 is the first formal signal that this environment is changing. The practical tools are not yet available, but the policy direction is set at the State Council level.

For the device and consumable portfolio: the current path is unchanged. Innovation in medical devices is recognised and encouraged at the regulatory level through NMPA’s Special Review Pathway for Innovative Medical Devices. But that recognition does not currently confer pricing protection or VBP exemption. Device companies that want to position a product as innovation-protected need to watch for a separate NMPA/NHSA instrument that would mirror the No. 9 logic on the device side. Until that instrument exists, the pathway remains: regulatory approval, market listing, procurement platform registration, and, for high-volume standardised products, eventual VBP inclusion.

For the ophthalmic portfolio specifically: premium intraocular lenses occupy an instructive position. Trifocal and EDOF IOLs were included in the fourth national VBP round for high-value consumables in 2023, which means they have already been treated as multi-supplier, market-mature products rather than protected innovations. Reversing that classification for existing products would require a separate policy intervention. What Document [2026] No. 9 creates, however, is a policy framework that a genuinely novel ophthalmic device, one meeting NMPA’s innovation criteria and not yet subject to VBP, could eventually benefit from, if and when device-side rules are established. The window is not open yet, but the policy architecture that would open it is now visible.

Key Implications

State Council Office Notice Document [2026] No. 9 is the most significant national drug pricing document since China’s 2015 price liberalisation, and it establishes an unambiguous policy direction: high-value innovation warrants protected pricing at launch. For pharmaceutical portfolios, the strategic implication is immediate; China’s historical role as a late or low-priority launch market requires reassessment. For device and consumable portfolios, the policy-execution gap is substantial: the document’s logic does not transfer automatically, and the separate regulatory instruments needed to make it operational on the device side have not yet been drafted. Companies with mixed drug-device portfolios should evaluate their China innovation pipeline through both lenses simultaneously, and monitor NMPA and NHSA for device-side implementation signals that would operationalise the No. 9 framework for high-value consumables.

Commercial Execution Brief

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.

— The OphthalLogix Intelligence Team

Subscribe now

China’s medical device listing system is no longer a one-time registration. On 17 April 2026, Zhejiang province’s drug and device procurement centre published notice 11330000MB18470516/2026-03450, suspending seven medical device products from online trading due to classification code non-compliance. Three weeks earlier, Shenzhen’s public resources trading centre issued a separate notice requiring non-selected IOL and sports medicine products to adjust listing prices to comply with provincial price ceilings, with products failing to respond within the objection window facing delisting. These are not isolated events: since January 2025, over ten provinces, including Hebei, Shandong, Shaanxi, Hunan, Heilongjiang, Jiangxi and Hubei, have initiated listing data governance actions. China’s device listing system is transitioning from a one-time registration to an active, ongoing compliance obligation.

What Changed, and Why It Matters

The policy-execution gap here is straightforward: most manufacturers entered China’s provincial listing platforms when their products launched and have not revisited those filings since. The regulatory assumption, ‘once listed, always listed’, is no longer valid. Listing status is now subject to active monitoring, price comparison across provinces, and classification code validation. Failure on any of these dimensions triggers suspension.

Three Conditions That Now Trigger Suspension

Provincial rules vary in detail but converge on three suspension triggers:

1. Price-linkage overdue

A lower listing price appears in another province. The manufacturer must update the local price within 30 calendar days. Non-update confirmed = suspension, typically 1 year.

30-day window. No other violation required.

2. Inaction on platform migration

Hubei’s 2025 system migration required all listed products to confirm data bindings by a set date. Products with no confirmation were excluded from the new platform automatically.

Deadline-driven. Silent = suspended.

3. Classification code mismatch

The Zhejiang April 2026 suspension: products were listed under a procurement category that did not match their registered device classification. Seven products from one manufacturer (peripheral vascular intervention devices, not ophthalmic), all suspended on the same notice.

Discovered via platform data governance audits.

The Zhejiang case involved peripheral vascular intervention devices, not ophthalmic products. Its significance for IOL manufacturers is structural: it demonstrates that classification code mismatch is now an active suspension trigger alongside the two previously observed mechanisms. The enforcement infrastructure does not distinguish by therapeutic area.

Zhejiang adds a fourth dimension: category-wide exposure. Under Zhejiang’s price-linkage rules, if a manufacturer has six or more products in a single category with non-compliant linkage filings, the entire category is suspended, not just the specific products. For manufacturers with broad product portfolios, one compliance gap can remove an entire device line from the province’s procurement platform simultaneously.

Why This Is Not Indirect for IOL Manufacturers

A common assumption is that high-end intraocular lenses, multifocal, EDOF, toric premium, are largely insulated from listing compliance issues because their principal revenue comes from out-of-pocket patients rather than insurance reimbursement. This assumption is incorrect in a specific, consequential way.

Listing is not a precondition for insurance payment. It is a precondition for any public hospital procurement. A product that is not entered into a province’s healthcare procurement sub-system cannot be ordered by a public hospital, regardless of whether the patient intends to pay out of pocket. In clinical practice, this means a surgeon has no pathway to recommend a product to a patient if it does not appear in the hospital’s billing catalogue, not because of clinical judgment, but because the administrative channel does not exist.

This is not theoretical. In ophthalmic clinical practice before national VBP implementation, the standard workflow was as follows: before a physician could present any IOL option to a patient, whether single-focus, toric, or multifocal, the product had to be entered into the hospital’s billing catalogue. A product absent from that system could not be priced, could not be consent-documented, and could not be ordered. The physician’s judgment about what was clinically appropriate was constrained entirely by what appeared in that catalogue. A listing suspension does not reduce a product’s visibility to surgeons. It removes it.

Zhejiang’s medical security bureau has built real-time digital monitoring of IOL procurement execution across its public hospitals, publishing compliance rates at the institutional level. The infrastructure for detecting listing anomalies is already operating. The April 2026 suspension is a routine output of that infrastructure, not an exceptional enforcement action.

The Precedent: What Happened to Zeiss and an IOL Import Agent

Two cases define the outer boundary of this risk. In October 2025, the national high-value device joint procurement office cancelled Carl Zeiss Meditec AG’s VBP selection status for its bifocal non-toric IOL product (registration number: 国械注进20153161147) after a quality inspection found the product’s spectral transmittance did not meet the required standard. The suspension cascaded across multiple provinces, including Shanghai, Zhejiang, Guangdong, Ningxia and Guangxi. The lesson: listing status is not product-level, it is enterprise-level. A quality or compliance event affecting one SKU generates platform-wide risk flags for the brand.

In early 2023, an IOL import agent, Hangzhou Xiehe Medical Supplies Co., Ltd (杭州协合医疗用品有限公司), acting as the domestic representative for an Indonesian manufacturer’s IOL product, voluntarily withdrew from a Shanghai municipal IOL procurement after winning the bid at RMB 989 per lens. Under Shanghai’s rules, this triggered a two-year suspension of all that company’s IOL products from Shanghai procurement and listing applications, effective February 2023 to February 2025. One decision: two years of market exclusion across an entire product category.

OphthalLogix Assessment: Who Is Exposed, and What to Do

Listing compliance rules are not drafted to disadvantage foreign manufacturers specifically. But their practical impact is uneven based on execution capacity, not intent.

Manufacturers with dedicated, China-based market access teams that actively monitor provincial price databases, track platform migration deadlines, and audit product classification codes are relatively advantaged as smaller or less-resourced competitors are cleared from platforms. The governance trend is accelerating the consolidation of market access capacity at established players.

The countervailing risk: large multinational manufacturers with broad product portfolios face disproportionate exposure to Zhejiang’s category-wide suspension rule. A multi-SKU ophthalmic portfolio is precisely the structure most likely to carry the volume of non-compliant linkage filings that trigger a category suspension. Size and breadth are not a shield here; they increase the surface area for compliance gaps.

The self-audit window is now. Zhejiang’s April 2026 public notice closes on 23 April. If your products are listed in Zhejiang, the question of whether any of them fall under the categories subject to active governance is answerable in minutes on the provincial platform, and the cost of discovering a problem now is a fraction of the cost of receiving a suspension notice.

Key Implications

China’s medical device listing system shifted in 2025–2026 from passive registration to active compliance maintenance. Manufacturers affected are all entities with products on provincial procurement platforms, both foreign and domestic, but the practical burden falls heaviest on those without dedicated market access monitoring. For IOL manufacturers specifically, the listing-suspension risk is not indirect: a suspended product disappears from the hospital procurement channel regardless of whether the end patient is paying out of pocket. The immediate action is a platform audit of active listing status, price-linkage compliance, and product classification accuracy across key provinces, prioritising Zhejiang and Guangdong, given their demonstrated enforcement activity in April 2026.

Subscribe now

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.

— The OphthalLogix Intelligence Team

The document landed quietly on 13 April. National Health Commission Office Notice 【26】No. 117, the Adult Cataract Surgical Operating Standard (2026 Edition), was published on nhc.gov.cn and forwarded to every provincial health authority in China. Most industry observers treated it as clinical housekeeping. That reading is incorrect.

This piece explains why the Standard is a structural market event, and what the execution gap between policy text and clinical reality means for the IOL market over the next 12 to 24 months.

I. The Legal Category Shift: From Recommendation to Obligation

China’s ophthalmology practice has operated for years under a layered stack of expert consensus documents and clinical guidelines, all advisory, none binding. The 2019 Expert Consensus on Multi-focal IOL, the 2023 Clinical Guidelines for Adult Cataract Surgery, and the 2025 Expert Consensus on Presbyopia-correcting IOL shaped practice but created no enforceable obligation on hospitals or physicians.

The 2026 Standard is different in kind. Issued under the NHC’s administrative authority, it is a regulatory norm, not an academic recommendation. It binds provincial health commissions in quality oversight, informs hospital accreditation, and establishes the reference standard for adverse-event adjudication.

A hospital that deviates from the Standard without documented clinical justification now carries regulatory and legal exposure it did not carry before 13 April.

II. Three Structural Changes That Matter Commercially

Premium IOL categories now have a statutory chapter. The Standard’s Part III dedicates four subsections to IOL selection: IOL classification, monofocal IOL, toric IOL, and presbyopia-correcting IOL, the last of which covers multifocal, trifocal, EDOF, and enhanced monofocal designs. This is the first time a Chinese administrative regulation has explicitly codified presbyopia-correcting lenses as a recognised category with dedicated operating standards. Hospitals now have an official compliance basis for implanting premium lenses that did not exist in any prior binding document.

Pre-operative assessment and documentation requirements are now obligations. The Standard specifies systematic pre-operative evaluation across biometry, corneal topography, and patient communication. The pre-operative workup required to justify a premium IOL implant is now documented, traceable, and auditable. This raises the minimum capability bar for any facility offering a premium lens pathway.

Operating theatre standards are codified. Part VI sets requirements for air cleanliness, layout, humidity, ventilation, equipment, and infection control. Best practice moves to a mandated standard.

III. The Execution Gap

The Notice tells provinces to “organise implementation”, with no unified deadline. Based on comparable NHC standard rollouts, tier-one markets (Beijing, Shanghai, Guangdong, Zhejiang, Sichuan) will move within months. Secondary and western-province markets will take 12 to 24 months.

This is a market-segmentation event disguised as a regulatory document. Compliance capability, equipment, trained staff, and documented processes will determine which facilities can credibly offer a premium IOL pathway, not administrative intent.

IV. Four-Layer Impact

Access layer: Premium IOL implantation now has an official compliance basis. Hospital formulary submissions can reference Part III directly, reducing procurement committee friction. Immediate to 3 months.

Pricing layer: The Standard provides the clinical rationale for premium pricing. Value-analysis committees now have an administrative document that distinguishes premium surgery from standard cataract extraction. 3–6 months.

Payment layer: The NHC’s clinical documentation framework could, in future DRG/DIP 3.0 refinements, support differential reimbursement coding for premium procedures. This is analytical inference, not confirmed policy linkage, but the simultaneous movement of both policy tracks is worth noting. 6–18 months.

Behaviour layer: For hospitals building premium cataract programmes, the Standard provides an implementable clinical template that accelerates capability diffusion in second-tier cities. 6–24 months.

V. What This Means for Manufacturers

The Standard is brand-neutral but not capability-neutral.

For international manufacturers, such as Alcon, Zeiss, and Johnson & Johnson Vision, the Standard reinforces the value of existing training infrastructure and clinical evidence packages. These manufacturers are positioned to help tier-one hospitals build compliant premium programmes quickly.

For domestic manufacturers, the Standard creates a clearer regulatory roadmap for premium product positioning. A domestic player that invests in Standard-aligned training and pre-operative assessment tools could compress the brand credibility gap faster than the historical trajectory suggests.

VI. A Clinical Observation Worth Adding

Premium IOL outcomes depend on patient selection, surgical technique, and expectation management in roughly equal measure. The Standard’s emphasis on documented pre-operative assessment addresses a real and persistent problem: patients entering a premium IOL consultation arrive with heterogeneous prior knowledge, product comparisons from online platforms, peer recommendations, and brand associations that often bear a limited relationship to clinical suitability.

Manufacturers who build Standard-aligned patient communication tools, covering functional outcome expectations, adaptation timelines, and differences between premium categories, will have a genuine commercial differentiator. The value is risk reduction for the hospital, not marketing material.

VII. The One Decision This Forces Now

For any commercial team with China premium IOL exposure: determine whether your hospital submission packages, formulary justification materials, and physician training programmes explicitly reference the Standard’s relevant chapters. They should. The Standard is now the compliance anchor.

For investors: a structural uncertainty has been resolved. Premium IOL surgery in China is now administratively legitimised. The regulatory grey-zone question has been answered.

—OphthalLogix Intelligence Team

OphthalLogix continues to track the market weekly. Please subscribe if you are interested in the articles in OphthalLogix.

The commercial execution brief (stakeholder action frameworks, geographic prioritisation) is available to subscribers via request.

Commercial Execution Brief

This report is for informational purposes only and does not constitute professional advice. OphthalLogix accepts no liability for decisions made based on this content.

Over the past twelve months, the Chinese intraocular lens market has settled into three coexisting reimbursement regimes. Winning prices from the 4th national VBP round have become binding payment standards. Enforcement has begun.

We have compiled a short reference PDF that captures the current state of the landscape in three pages: the four-sentence summary we would take to an HQ meeting, the 4th VBP anchor price table, and the four policy developments of the past twelve months.

The PDF is free to download below. No sign-up required to read; subscription is open if you want to follow ongoing work on this topic.

China IOL Reimbursement Landscape

— OphthalLogix Intelligence Team

This report is for informational purposes only and does not constitute professional advice. OphthalLogix accepts no liability for decisions made based on this content.

Most descriptions of the Chinese intraocular lens market open with a national number: annual cataract procedures, average selling prices, and premium penetration rates. The numbers are not wrong. The market they describe, however, has quietly disappeared. There is no single Chinese IOL market any longer. There are three, and the gap between them is wide enough to matter.

Regime A · Beijing. Hard cap, with a legitimate escape valve.

Beijing caps IOL reimbursement by lens category, most recently RMB 1,835 per lens, under Beijing MSA [2020] No. 28. Patients may, however, legitimately pay the delta to a premium lens against a signed consent form. The mechanism exists on paper and is referenced in current reimbursement notices.

Regime B · Guangzhou. The reform of March 2025.

On 10 February 2025, the Guangzhou Medical Security Administration issued notice [2025] No. 1, removing the IOL reimbursement cap and moving to proportional payment. Guangzhou is, at the time of writing, the only tier-one Chinese metropolitan market to have done so. It is the single largest reimbursement change we have recorded in the past twelve months.

Regime C · DRG / DIP bundling.

Shanghai, Zhejiang, Jiangsu, Sichuan, Chongqing and others have moved cataract care into DRG or DIP case bundling. Under these regimes, the lens becomes a cost item inside a fixed case payment rather than a separately reimbursable consumable. That distinction, on its own, is enough to change the commercial logic of any IOL above the bundle’s implied lens allowance.

The 4th VBP anchors · binding for the next two to three years.

The 4th national volume-based procurement round is the second fact on which any current analysis of this market has to rest. The winning prices are now the payment standard in every province that has published an implementation notice. Any delta above is paid by the patient against signed consent.

Enforcement has begun. In April 2025, the NHSA disqualified an Indonesian supplier from the IOL VBP for breach of its bidding commitments and suspended its eligibility through October 2026, the first public enforcement action since the 4th round opened. Commitments made under VBP should now be treated as enforceable. The renewal window opens in the second half of 2026, and the regulator’s language around the 6th round’s “anchor price” mechanism (January 2026) signals that the next round will not repeat the deep cuts of the last.

Where we go from here

This is the first public release of OphthalLogix Intelligence. We intend to keep tracking this market as it moves, provincial reimbursement updates, VBP enforcement and renewal, and hospital-level execution of the policies already on paper. We will publish further work as the picture clarifies.

If the subject is useful to you, subscribe, and you will be notified when we next publish.

— The OphthalLogix Intelligence Team

This report is for informational purposes only and does not constitute professional advice. OphthalLogix accepts no liability for decisions made based on this content.

OphthalLogix Intelligence tracks the gap between healthcare policy and hospital-level execution in China's ophthalmic device market. We bridge the critical gap between clinical realities and administrative logic.

【Executive Summary: The Shift in Power Dynamics】

China’s ophthalmology market is undergoing a silent but total transformation. The era of monolithic, purely administrative tendering is over. It has been replaced by a sophisticated, hybrid environment, a “dual-track” decision-making process where clinical authority and administrative control constantly negotiate.

The most consequential implication is this: the official tender is merely a "ticket to play." The real procurement decisions are often finalised in the quiet synergy of the operating room and the strategic calculus of the administrative office, long before the first official document is ever published.

【Core Insights: Redefining the China Logic】

1. Efficiency Economics: Time as the True Premium

In China’s high-volume clinical environments, surgical turnover is the ultimate metric. While international players often focus on technical specifications, domestic challengers are winning by optimising “workflow alignment.” By embedding technicians on-site and tailoring support to the surgeon’s rhythm, they create a high switching cost that is independent of the machine’s parameters and entirely driven by clinical efficiency.

2. Consistency Economics: The Moat of Bureaucratic Inertia

Why do hospitals maintain the status quo even when more cost-effective alternatives appear? Because in the Chinese administrative logic, the cost of “doing nothing” is often the lowest. True market dominance is achieved when your presence is so deeply embedded into the hospital’s operational rhythm that “replacing the vendor” becomes bureaucratically inconvenient, expensive, and fraught with administrative risk.

3. The Performance of Alignment

Successful market access is no longer a one-way lobbying effort; it is an art of multi-dimensional alignment. You must simultaneously satisfy the surgeon’s pursuit of clinical excellence and the administrator’s demand for operational security and cost metrics. The winners are those who can navigate the delicate friction between informal negotiation and formal documentation.

【The Bottom Line】

In China, market access is no longer an exercise in compliance; it is a performance of alignment.

Future premiums will not be commanded by the “Imported” label alone. They will be earned by those who prove they understand the surgeon’s heartbeat and the administrator’s administrative safety better than anyone else in the room.

Please access the detailed brief here:

The Hidden Procurement Ecosystem

For business inquiries: ophthallogix@gmail.com

This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China's healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.